CenterWatch
  • Search Clinical Trials
  • Clinical Trial Listings
  • Volunteer
  • Learn About Clinical Trials

Ōita-city, Japan

< 2 Miles
Filters

Type

Distance
Age
0
0
Gender
Trial Phase
Sponsor
  • A Study to Assess the Safety, Tolerability, Efficacy, and Drug Levels of BMS-986369 (Golcadomide) in Participants With Relapsed or Refractory T-cell Lymphomas in Japan (GOLSEEK-3)

    Phase

    1/2

    Span

    360 weeks

    Sponsor

    Bristol-Myers Squibb

    Oita

    Recruiting

  • Study to Evaluate the Efficacy and Safety of K-877-ER and CSG452 in Participants With NASH With Liver Fibrosis

    Phase

    2

    Span

    177 weeks

    Sponsor

    Kowa Research Institute, Inc.

    Oita

    Recruiting

  • Japan Post-Marketing Surveillance for Peficitinib to Assess Safety and Effectiveness in the Patients With Rheumatoid Arthritis

    This is a mandatory Post-Marketing Surveillance (PMS) requested by Pharmaceuticals and Medical Devices Agency (PMDA) as a part of the Japan-Risk Management Plan (J-RMP).

    Phase

    N/A

    Span

    331 weeks

    Sponsor

    Astellas Pharma Inc

    Oita

    Recruiting

  • Study To Assess Frequency Of Serious Infections In Clinical Practice In Japan For Adult Participants With Rheumatoid Arthritis Receiving Oral RINVOQ Tablets

    Phase

    N/A

    Span

    280 weeks

    Sponsor

    AbbVie

    Oita

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of Icotrokinra (JNJ-77242113) in Biologic-experienced Participants With Active Psoriatic Arthritis

    Phase

    3

    Span

    197 weeks

    Sponsor

    Janssen Research & Development, LLC

    Oita

    Recruiting

  • A Study to Evaluate the Efficacy and Safety of JNJ-77242113 (Icotrokinra) in Biologic-naïve Participants With Active Psoriatic Arthritis

    Phase

    3

    Span

    201 weeks

    Sponsor

    Janssen Research & Development, LLC

    Oita

    Recruiting

  • Effects of LY3848575 Versus Placebo in Participants With Painful Distal Sensory Polyneuropathy

    Phase

    2

    Span

    110 weeks

    Sponsor

    Eli Lilly and Company

    Oita

    Recruiting

  • Imfinzi/Imjudo uHCC Japan PMS _ Japan Post-Marketing Surveillance (PMS) Study

    This investigation will be conducted to collect information of safety in patients with unresectable hepatocellular carcinoma (HCC) treated with the combination therapy of IMJUDO 25 mg, 300 mg and IMFINZI Intravenous Infusion 120 mg, 500 mg or with IMFINZI monotherapy under actual use in the post-marketing setting. The investigation will be conducted as one of the additional pharmacovigilance activities in the Japan Risk Management Plan of IMJUDO and IMFINZI in compliance with the Ministerial Ordinance on Good Post-marketing Study Practice (GPSP Ordinance) and for the purpose of application for reexamination under Article 14-4 of the Act on Securing Quality, Efficacy and Safety of Products Including Pharmaceuticals and Medical Devices.

    Phase

    N/A

    Span

    191 weeks

    Sponsor

    AstraZeneca

    Oita

    Recruiting

  • TEZSPIRE (Tezepelumab) Asthma Japan Post-Marketing Study (PMS)

    The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of Tezspire. 1. Development of related AEs 2. Contributing factors possibly having an impact on the safety and effectiveness 3. Development of unexpected related AEs This investigation will be conducted to support the application for re-examination specified in Article 14-4 of the Act on Securing Quality, Effectiveness and Safety of Products Including Pharmaceuticals and Medical Devices.

    Phase

    N/A

    Span

    346 weeks

    Sponsor

    AstraZeneca

    Oita

    Recruiting

  • A Study to Evaluate Astegolimab in Participants With Chronic Obstructive Pulmonary Disease

    Phase

    3

    Span

    219 weeks

    Sponsor

    Hoffmann-La Roche

    Oita

    Recruiting

1-10 of 20
CenterWatch

5000 Centregreen Way, Suite 200
Cary, NC, 27513, USA

Phone: 609.945.0101

  • Disclaimer
  • Privacy Policy
  • Term of Use
  • Do Not Sell My Personal Information